Treatment of adult inflammatory myositis with rituximab: An emerging therapy for refractory patients
Majumudar S, Hall HS, Zimmermann B. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol. 2009;15:338-340.
Cutaneous vasculitis in a patient with dermatomyositis without muscle involvement
Kadoya A, Akahoshi T, Sekiyama N, et al. Cutaneous vasculitis in a patient with dermatomyositis without muscle involvement. Intern Med. 1994;33:809-812.
A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups
Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine Baltimore. 1991;70:360-374.
Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies
Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation offunctionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol. 1986;17:704-721. (Pubitemid 16070409)
Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome [3]
DOI 10.1136/ard.2005.047308
Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:1116-1117. (Pubitemid 44133281)
